. Author manuscript; available in PMC: 2017 Mar 7.

Published in final edited form as: Sci Transl Med. 2016 Sep 7;8(355):355ra117. doi: 10.1126/scitranslmed.aag1180

Table 1.

Patient characteristics and in vitro treatments.

Pt. No.	source	Blast (%)	BCR-ABL status	Treatments and responses	In vitro treatment and assays				% Q Cells	Days of co-culture with MSC
Pt. No.	source	Blast (%)	BCR-ABL status	Treatments and responses	Cells in which apoptosis was determined		WB/PCR	Bcl-X_L/Mcl-1 KD	% Q Cells	Days of co-culture with MSC
1	PB	91	T315I, E255K	Resistant to imatinib; treated with chemotherapy and dasatinib	P/Q	bulk/CD34⁺38⁻/CD34⁺38⁺			9.4	6
2	PB	89	T315I, E255V	Resistant to imatinib, dasatinib, nilotinib, and ponatinib	P/Q	bulk/CD34⁺38⁻ CD34⁺38⁺	protein/RNA	siRNAs	15.9	7
3	PB	83	H396R	Failed imatinib, dasatinib, and nilotinib.	P/Q	bulk/CD34⁺38⁻ CD34⁺38⁺		siRNAs	22.1	10
4a	PB	89	T315I, E255B	Resistant to imatinib, nilotinib, dasatinib, and ponatinib; treated with CECA, ponatinib, and dasatinib		bulk/CD34⁺38⁻ CD34⁺38⁺	protein/RNA	siRNAs
5	PB	80	No mutation	Resistant to imatinib, and dasatinib		bulk	protein/RNA
6	BM	93	No mutation	Failed imatinib; treated with nilotinib		bulk/CD34⁺38⁻ CD34⁺38⁺
4b	PB	62	T315I, E255V	Resistant to imatinib, dasatinib, and ponatinib; treated with nilotinib, decitabine, and dasatinib	P/Q				7.7	6
7	PB	24	No mutation	Resistant to imatinib; treated with nilotinib	P/Q				6.8	8
8	PB	11	No mutation	Resistant to imatinib, dasatinib, nilotinib, and ponatinib; treated with decitabine, dasatinib, and bosutinib	P/Q				14.4	7

Abbreviations: Pt, patients; No, number; CECA, cyclophosphamide, etoposide, carboplatin, and cytosine arabinoside; P/Q, apoptosis in proliferating and quiescent cells; WB, western blot; % Q cells, % quiescent cells over total CD34⁺ cells.